Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10952661 | 0.89 | LMNA (0.49) | HTR2ALMNASIGMAR1TSHRADRA1D | |
| SCHEMBL10882868 | 0.80 | CCR1 (0.34) | HTR2ALMNAHTR2CDRD2SLC6A2 | |
| SCHEMBL22678704 | 0.79 | PDK2 (0.42) | ALDH1A1 | |
| SCHEMBL11523571 | 0.76 | LMNA (0.42) | LMNASLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL14707057 | 0.74 | KMT2A (0.36) | HTR2CSLC6A2ALDH1A1MAPT | |
| SCHEMBL7039204 | 0.74 | CHRM3 (0.36) | ALDH1A1 | |
| SCHEMBL14659945 | 0.74 | ADRA1D (0.38) | SIGMAR1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL21246111 | 0.73 | PDK2 (0.37) | — | |
| SCHEMBL11480489 | 0.73 | ALPL (0.41) | TSHRADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL19130507 | 0.71 | SIGMAR1 (0.41) | HTR2ALMNASIGMAR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | HTR2A 1110/4885LMNA 4094/4885HTR2C 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.